Effects of Gastrointestinal-Type Chemotherapy in Women with Ovarian Mucinous Carcinoma

Katherine C. Kurnit, Abdulrahman K. Sinno, Bryan M. Fellman, Aaron Varghese, Rebecca Stone, Anil K. Sood, David M. Gershenson, Kathleen M. Schmeler, Anais Malpica, Amanda N. Fader, Michael Frumovitz

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To estimate whether gastrointestinal-type chemotherapy was associated with improved survival compared with standard gynecologic regimens for women with ovarian mucinous carcinoma. METHODS: We conducted a retrospective cohort study of patients with ovarian mucinous carcinoma who received postoperative adjuvant chemotherapy at two academic centers. Demographic and clinical information was abstracted from the medical records. Gastrointestinal-type chemotherapy contained 5-fluorouracil, capecitabine, irinotecan, or oxaliplatin. Gynecologic regimens included standard carboplatin or cisplatin. Bevacizumab treatment was allowed in both groups. Summary statistics were used to compare baseline characteristics; Kaplan-Meier product-limit estimator was used to compare survival outcomes. RESULTS: Fifty-two patients received either gastrointestinal-type chemotherapy (n=26; 50%) or a standard gynecologic regimen (n=26; 50%). Three-quarters of tumors were early-stage (I or II), 68% grade 1 or 2 and 88% of patients had no gross residual disease after surgery. Patients receiving gastrointestinal-type chemotherapy were more likely to receive bevacizumab (50% vs 4%; P<.001), but there were no other differences in clinical or demographic characteristics. Unadjusted overall survival analyses showed that gastrointestinal-type chemotherapy was associated with better overall survival (hazard ratio 0.2, 95% CI 0.1-0.8), as were early stage tumors and having no gross residual disease. CONCLUSION: Gastrointestinal-type chemotherapy with or without bevacizumab was associated with improved survival and should be considered in patients with ovarian mucinous carcinoma requiring adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)1253-1259
Number of pages7
JournalObstetrics and gynecology
Volume134
Issue number6
DOIs
StatePublished - Dec 1 2019

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Effects of Gastrointestinal-Type Chemotherapy in Women with Ovarian Mucinous Carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Kurnit, K. C., Sinno, A. K., Fellman, B. M., Varghese, A., Stone, R., Sood, A. K., Gershenson, D. M., Schmeler, K. M., Malpica, A., Fader, A. N., & Frumovitz, M. (2019). Effects of Gastrointestinal-Type Chemotherapy in Women with Ovarian Mucinous Carcinoma. Obstetrics and gynecology, 134(6), 1253-1259. https://doi.org/10.1097/AOG.0000000000003579